Cancer patients may soon get immunotherapy at home instead of the clinic

NCT ID NCT06265285

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug at home after initial clinic doses, and researchers will measure changes in satisfaction and comfort.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nivolumab (Opdivo)
What this could lead to
If successful, this could show that giving cancer immunotherapy at home is safe and improves patients' quality of life, reducing travel and time burdens.
What could go wrong
This is a small, early-phase pilot study with only 50 participants, so results may not apply to everyone. Home care may have safety or logistical challenges not seen in clinic settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.